I think most LTHs will see through your ambiguity as designed to sow doubt about the analysis of @anatol and the outlook for LTR share price. Asking questions is generally NOT what anatol does! Unlike you, he provides the analytical response to the FUD that is spread by many. What I found very interesting of late has been the commonality of commentary and views about sourcing African spod and lepdolite by the likes of Ken Brinsden in his recent webinar with that of anatol. If you read the most recent posts from anatol he explains how marginal the economics of particularly the Chinese lepidolite is, bearing in mind its cost of refining and the "published" market prices for refined product.
Furthermore, your comment about the LTR debt carry is nonsense! LTR now has the cheapest debt financing in mining, and effectively issued new equity at double the prevailing market price which makes us virtually free of any debt issues. Check your housing loan rate against the LTR debt finance and see how they compare? The "high OPEX you refer to is also a furphy, as it may be high driven by the initial mining costs to get to the ore and then build the stockpile which is effectively a long term investment. Unfortunately that cost is brought to account as OPEX as it cannot be capitalised. Instead you should be comparing the forecast 10 year average if you are genuinely a LTHer. That compares very well with other spod producers but more than brines.
I will back anatol's commentary as being truthful and insightful over the media stories and scuttlebut on most forums. In terms of opaqueness, I think you said so yourself about the information vacuum, so why rely on it?
regards
DF
- Forums
- ASX - By Stock
- LTR
- ASX Today
LTR
liontown resources limited
Add to My Watchlist
0.71%
!
69.5¢

ASX Today, page-41401
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
69.5¢ |
Change
-0.005(0.71%) |
Mkt cap ! $1.688B |
Open | High | Low | Value | Volume |
70.0¢ | 72.0¢ | 68.0¢ | $6.392M | 9.154M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 25246 | 69.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
70.0¢ | 175257 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 25246 | 0.695 |
11 | 336717 | 0.690 |
6 | 289391 | 0.685 |
16 | 282171 | 0.680 |
17 | 333206 | 0.675 |
Price($) | Vol. | No. |
---|---|---|
0.700 | 175257 | 7 |
0.705 | 172480 | 7 |
0.710 | 150000 | 6 |
0.715 | 174000 | 7 |
0.720 | 503348 | 16 |
Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online